The company said it will stop the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over placebo.

Sanofi (NASDAQ:SNY) said on Thursday that it is discontinuing the late-stage trial for its vaccine to prevent E. coli bacteria infection as it failed to demonstrate sufficient efficacy. The vaccine for extraintestinal pathogenic E.

Johnson & Johnson said on Thursday it will discontinue a late-stage study of an experimental E.coli vaccine it was developing in partnership with Sanofi. The drugmaker said its decision was based on t